Core Viewpoint - Novo Resources Corp. has announced a capital raising initiative aimed at raising gross proceeds of C$7.9 million (approximately A$8.2 million) through a placement of units and Chess Depository Interests (CDIs) to institutional and sophisticated investors [3][9]. Group 1: Capital Raising Details - The capital raising will involve the issuance of approximately 16.8 million units at C$0.10 per unit and approximately 61.1 million CDIs at A$0.105 per CDI [3]. - The placement will occur in two tranches, with Tranche 1 expected to raise approximately C$6.0 million (around A$6.2 million) and Tranche 2 expected to raise approximately C$1.9 million (around A$2.0 million), subject to shareholder approval [11]. - Major shareholder Northern Star Ltd has committed to participate in the placement up to its pro-rata holding of approximately 9% [5]. Group 2: Use of Proceeds - The funds raised are intended to be primarily used for planned drilling and reconnaissance activities across priority projects throughout 2026, as well as for general working capital purposes [9]. - Drilling will focus on high-priority projects in Western Australia, including Wyloo, Balla Balla, and Teichman, with programs set to commence in Q2 2026 [10][18]. Group 3: Project Highlights - At Wyloo, a proposed 1,500m RC drill program will target a high-grade vein array, with peak rock chip assays returning 0.93 g/t Au, 482 g/t Ag, 1.29% Sb, 2.62% Cu, 9.7% Pb, and 15.95% Zn [10]. - The Balla Balla project will see a planned 6,000m AC drill program aimed at expanding on a previously completed 5,996m Air Core drill program that identified a large polymetallic geochemical anomaly [18]. - The Teichman project will have a planned 2,000m RC drill program focusing on two shear zones that returned significant gold assays [18]. Group 4: Additional Information - Novo continues to receive strong annual dividends from its investment in the San Cristobal Mine, which has delivered excellent returns [13]. - The company has a significant land package covering approximately 4,160 square kilometers in the Pilbara region of Western Australia and is focused on discovering standalone gold and copper projects with over 1 million ounces of development potential [21].

Vancouver, British Columbia--(Newsfile Corp. - February 25, 2026) - Kincora Copper Limited (ASX: KCC) (the Company) requests a trading halt in relation to the Company's securities (KCC) listed on the Australian Securities Exchange (ASX) in accordance with ASX Listing Rule 17.1. The trading halt is requested pending an announcement by the Company to the market regarding a capital raising (Purpose). In accordance with ASX Listing Rule 17.1, the Company provides the following information in relation to the re ...

Core Insights - Beach Cities Commercial Bank reported its financial results for the fourth quarter of 2025, highlighting robust growth and a focus on sustainable profitability [1] Financial Performance - The bank's net loss for Q4 2025 was $117.6k, a decrease from a profit of $14.5k in Q3 2025, but adjusted net income was $22.4k when excluding credit provisions [1] - Year-to-date loss for 2025 was $605.7k, significantly reduced by 87% from a loss of $4.5 million in 2024 [1] - Total deposits reached $143.5 million, marking a 9% increase from Q3 2025 and a 27% increase year-over-year [1] - Gross loans amounted to $144.1 million, reflecting a 12% growth from Q3 2025 and a 36% increase from the previous year [1] - Total assets grew to $176.7 million, a 13% increase from Q3 2025 and a 35% increase year-over-year [1] Asset Quality and Liquidity - The bank maintained a reserve for credit losses of $1.412 million, equating to 0.98% of total loans, with no delinquent or non-performing assets reported [1] - Total liquidity was high at $28.3 million, representing 16.02% of total assets, with additional contingent borrowing sources of $18.7 million [1] Interest Income and Expenses - Total interest income for Q4 2025 was $2.87 million, a 2.2% increase from Q3 2025, while interest expense decreased by 6.1% to $1.17 million [1] - The bank's net interest margin stood at 3.82% as of December 31, 2025, supported by an average loan yield of 7.69% [1] Operational Efficiency - Total operating expenses for Q4 2025 were $1.62 million, a 4.8% increase from Q3 2025, with a decrease in salaries and benefits expenses [1] - The bank's non-interest income from loan sales increased by 277% year-over-year, although gains from loan sales in Q4 2025 were lower than in Q3 2025 due to external factors [1] Future Outlook - The bank plans to raise up to $5 million through a private placement offering to support its growth momentum [1] - The appointment of a new President/CEO is expected to further enhance the bank's strategic direction and operational capabilities [1]

Asia Pacific Equity Research 30 January 2026 This material is neither intended to be distributed to Mainland China investors nor to provide securities investment consultancy services within the territory of Mainland China. This material or any portion hereof may not be reprinted, sold or redistributed without the written consent of J.P. Morgan. China Insurance Capital raising cycle in the sector? Initial thoughts are that sector implications should be relatively limited According to Bloomberg news today, 30 ...

Core Viewpoint - Fermi (FRMI) has experienced a significant collapse in its stock price due to the withdrawal of a major counterparty, which has contributed to a 63% decline since October, highlighting valuation issues and challenges in capital raising [1][2][3]. Company Analysis - Fermi's market capitalization was $18 billion while it had only raised approximately $2 billion in total capital, indicating a severe valuation mismatch [2]. - The company faces the daunting task of generating $9 in value for every dollar raised, which is nearly impossible without flawless execution [3]. - The loss of the primary tenant raises concerns about the viability of Fermi's data center campus, although there may be other potential tenants [1][21]. Capital Raising Challenges - The ease of raising capital in hyped sectors often leads to poor investment outcomes, as seen in various market bubbles [4][5][6]. - Founders often benefit financially from capital raises regardless of long-term performance, creating misaligned incentives [6][7]. - Fermi's capital structure is challenged by significant dilution of equity investors due to management receiving shares at low prices [16][17]. Market Conditions - The current market environment shows that while there is high demand for data centers, Fermi's situation is complicated by the loss of its major tenant and the need for additional capital to build out infrastructure [21][25]. - The upcoming expiration of lock-up periods for shares may lead to increased selling pressure, further impacting the stock price [23]. Future Outlook - The bullish case for Fermi hinges on its ability to secure expedited access to power and attract new tenants, but significant hurdles remain, including the need for billions in additional capital [24][25]. - Despite the recent price drop, Fermi is still considered overvalued, and a bearish outlook persists until the valuation aligns more closely with future revenue potential [26].

Group 1 - Denali Therapeutics Inc. plans to offer and sell $200 million of its common stock and pre-funded warrants to certain investors in an underwritten public offering, with an additional $30 million option for underwriters [1] - The offering is subject to market conditions, and there is no assurance regarding its completion or the final terms [1] - Goldman Sachs, J.P. Morgan, Morgan Stanley, and Jefferies are acting as joint book-running managers for the offering, with H.C. Wainwright as co-manager [2] Group 2 - The shares will be offered under a Registration Statement on Form S-3, which became effective upon filing with the SEC on February 27, 2025, and a preliminary prospectus supplement will be filed [3] - Copies of the preliminary and final prospectus supplements can be obtained from the respective underwriters [4] Group 3 - Denali Therapeutics is a biotechnology company focused on developing biotherapeutics that can cross the blood-brain barrier using its proprietary TransportVehicle™ platform, aiming to deliver effective medicines for neurodegenerative and other serious diseases [6]

Financial Data and Key Metrics Changes - Fiscal first quarter revenue was $10.8 million compared to $4 million for the prior year period, primarily driven by $7.4 million in revenue from the sale of a built-to-suit property [12] - The company reported a net loss of $7.9 million for the quarter versus net income of $3 million a year ago, mainly due to unrealized losses on investments [13] - Adjusted EBITDA for the quarter was a loss of $500,000 compared to a gain of $1.3 million in the prior year period [13] - Fee-paying assets under management (AUM) grew 9% year over year to approximately $594 million, or 10% on a pro forma basis to approximately $601 million [4][12] Business Line Data and Key Metrics Changes - Monomoy BTS sold its second built-to-suit development property for over $7 million, generating a gain of over $500,000 [6] - Investment management and property management fees at Monomoy CRE increased 12% over the prior year period, driven by growth in fee-paying AUM and rental income [8] - GECC raised approximately $28 million in equity proceeds, including a $15 million private placement and $13 million through its At the Market Equity Program [8] Market Data and Key Metrics Changes - The REIT deployed over $13 million to acquire seven new properties at attractive cap rates [8] - GECC doubled its borrowing capacity under its revolver to $50 million, reducing the interest rate by 50 basis points [9] Company Strategy and Development Direction - The company aims to expand its platform, grow assets under management, and enhance profitability [4] - A transformative partnership with Kennedy Lewis Investment Management was established, committing up to $150 million in leverageable capital to accelerate real estate platform expansion [5] - The company is focused on growing fee-paying AUM and scaling its credit and real estate platforms [11][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strategic direction of the business and the ability to leverage fixed costs for growth [17][18] - Despite setbacks from First Branch's bankruptcy, the company believes it is in a strong position with ample deployable cash and a solid balance sheet [10][11] Other Important Information - The company ended the quarter with approximately $53.5 million in cash, providing flexibility for growth initiatives [11] - The stock repurchase program was expanded by $5 million to a total of $25 million, with 5.6 million shares repurchased for $10.9 million [11] Q&A Session Summary Question: Current growth trajectory and expense structure - Management indicated that the bulk of fixed costs are in place, and the focus is now on growth, particularly in real estate and BDC [17][18] Question: Information on Monomoy REIT - Management acknowledged the limited public information on Monomoy REIT, which focuses on industrial outside storage and has over 150 buildings [20][21] - The REIT has built a built-to-suit business and aims for potential public listing in the future [21][22]

Core Insights - The chip maker has been actively raising capital from various sources [1] Group 1 - The company is exploring multiple avenues for capital generation [1]

Core Points - Radiopharm Theranostics Limited has successfully raised approximately A$35 million through a private placement of new shares at A$0.03 per share, with significant participation from institutional investors including Lantheus Holdings, Inc. [1][5][6] - The company will also conduct a Share Purchase Plan (SPP) to raise an additional A$5 million for existing eligible shareholders, maintaining the same terms as the placement [3][6]. Placement Details - The placement involves the issuance of approximately 1,167 million new fully paid ordinary shares, with Lantheus investing A$7.6 million, increasing its shareholding to 14.5% [5][6]. - Each placement subscriber will receive one free attaching option for every share subscribed, with an exercise price of A$0.039 and an expiration date of October 31, 2027 [2][10]. Use of Funds - The funds raised will be allocated as follows: A$6 million for drug manufacturing, A$34 million for clinical trials, and A$19 million for administration and working capital, extending the funding runway into 2027 [4][7][6]. Shareholder Approval - The second tranche of the placement, amounting to A$22.5 million, will require shareholder approval at an upcoming Extraordinary General Meeting (EGM) anticipated in early December 2025 [9][10].

Core Viewpoint - GBM Resources has successfully raised A$39.85 million (approximately $26.14 million) through an institutional placement to accelerate exploration and development in its Drummond Basin gold portfolio in Queensland [1][3]. Fundraising Details - The placement involves issuing approximately 752 million new shares at A$0.053 each, which represents a 3.6% discount to GBM's last closing price and a 4.7% discount to its ten-day volume-weighted average price [2]. - Canaccord Genuity (Australia) acted as the lead manager and bookrunner, with Argonaut Securities co-leading the placement [2]. Use of Proceeds - Proceeds from the placement, along with existing cash reserves, will be allocated to enhance exploration and development activities at GBM's 100%-owned Drummond Basin assets, which contain mineral resources of around 1.84 million ounces [3]. - The funds will also support business development initiatives and general working capital [3]. Capital Raising Structure - The capital raising will occur in two tranches: the first tranche involves 600 million shares issued under existing placement capacity, while the second tranche consists of 151.9 million shares to Wise Walkers, pending shareholder approval [4]. - GBM CEO Daniel Hastings expressed satisfaction with the positive response to the placement and emphasized the importance of strengthening the balance sheet to support growth in existing resources and systematic exploration [4].